The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Galanin hyperinnervates surviving neurons of the human basal nucleus of meynert in dementias of alzheimer's and parkinson's disease: A hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia
Abstract
This study summarizes the findings from postmortem examination of the brains of 22 control cases without neurological deficit, 12 cases of senile dementia of the Alzheimer type (SDAT), and nine cases of Parkinson's disease (three without signs of intellectual deterioration, four with dementia, and two atypical with dementia nonresponsive to L‐dopa treatment). The aim of this study was to find the similarities and differences in galanin innervation of the cholinergic basal nucleus neurons in these dementing disorders as compared with controls. Immunocytochemistry with antibodies against galanin peptide and against choline acetyltransferase was applied on perfused brain preparations. Galanin peptide is present in the basal nucleus of Meynert neuron networks in the normal human brain: in local circuit neurons, in a number of galanin/cholinergic neurons, and in a feedback circuit (via collaterals) that terminate upon the cholinergic neuronal somata and dendrites. Thus, peptide galanin circuits could function as powerful modulators of the activities of basal nucleus cholinergic neurons, both within the basal forebrain and in their wider projections to the neocortex and amygdala. As galanin has been shown to inhibit cholinergic activity, this galanin network could suppress the activity of cholinergic neurons. In SDAT, there is a primary loss of cholinergic neurons compounded by a secondary reaction of the remaining cholinergic neurons to the terminal degeneration in the cortex. Galanin networks demonstrate an inverse relationship to the cholinergic cell loss. Galanin axons hypertrophy and hyperinnervate the remaining cholinergic neurons. In Parkinson's disease the loss of cholinergic neurons is accentuated by the presence of dementia: the hypertrophy of the galanin axonal networks on cholinergic neurons is dramatic in Parkinson's disease with dementia. These observations throw new light on the neurotransmitter bases for these dementias. Galanin controls cholinergic mechanisms in the basal nucleus of Meynert, and dementia is accompanied by augmentation of galanin innervation onto an already depressed population of cholinergic neurons, thus demonstrating an appreciable amount of plasticity even in aged brain. These findings suggest that the present therapy of cholinergic enhancement as a means to retard intellectual deterioration can by itself have little effect at best, in these dementias. The suppressive effect of galanin peptide has to be reduced or curtailed, perhaps concurrently with the treatment of the cholinergic deficit. It is suggested that the curtailment of galanin activity might be achieved by galanin peptide antagonists or by small organic compounds that react with the galanin receptor and that these may constitute new therapeutic approaches toward dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Mesulam, M. ‐., Mufson, E. J., Levey, A. I., & Wainer, B. H. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140206 · Cited by 1,962
Galanin — a novel biologically active peptide from porcine intestine
Tatemoto, K., Rökaeus, Å., Jörnvall, H., McDonald, T. J., & Mutt, V. (1983) · FEBS Letters · doi:10.1016/0014-5793(83)80033-7 · Cited by 1,490
Jacobowitz, D. M., & Palkovits, M. (1974) · Journal of Comparative Neurology · doi:10.1002/cne.901570103 · Cited by 1,248
The connections of the septal region in the rat
Swanson, L. W., & Cowan, W. M. (1979) · Journal of Comparative Neurology · doi:10.1002/cne.901860408 · Cited by 1,135
Mishkin, M. (1982) · Philosophical Transactions of the Royal Society of London. B, Biological Sciences · doi:10.1098/rstb.1982.0074 · Cited by 1,120
LEWIS, P. R., & SHUTE, C. C. D. (1967) · Brain · doi:10.1093/brain/90.3.521 · Cited by 966
The central cholinergic system studied by choline acetyltransferase immunohistochemistry in the cat
Kimura, H., McGeer, P. L., Peng, J. H., & McGeer, E. G. (1981) · Journal of Comparative Neurology · doi:10.1002/cne.902000202 · Cited by 966
Distribution of galaninlike immunoreactivity in the rat central nervous system
Melander, T., Hökfelt, T., & Rökaeus, A. (1986) · Journal of Comparative Neurology · doi:10.1002/cne.902480404 · Cited by 724
Cited by
Auld, D. S., Kornecook, T. J., Bastianetto, S., & Quirion, R. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00079-5 · Cited by 666
Neuropeptides in perspective: The last ten years
Hökfelt, T. (1991) · Neuron · doi:10.1016/0896-6273(91)90333-u · Cited by 618
Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S. E., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 587
Decker, M. W., & McGaugh, J. L. (1991) · Synapse · doi:10.1002/syn.890070209 · Cited by 524
Branchek, T. A., Smith, K. E., Gerald, C., & Walker, M. W. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01446-2 · Cited by 496
Chan‐Palay, V., & Asan, E. (1989) · Journal of Comparative Neurology · doi:10.1002/cne.902870308 · Cited by 495
Self-citationOn Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Giguère, N., Burke Nanni, S., & Trudeau, L.-E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00455 · Cited by 413
LANG, R., GUNDLACH, A., & KOFLER, B. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.05.009 · Cited by 376
Liu, A. K. L., Chang, R. C.-C., Pearce, R. K. B., & Gentleman, S. M. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1392-5 · Cited by 368
Anatomy and physiology of central galanin-containing pathways
MERCHENTHALER, I., LOPEZ, F., & NEGROVILAR, A. (1993) · Progress in Neurobiology · doi:10.1016/0301-0082(93)90012-h · Cited by 331
Lang, R., Gundlach, A. L., Holmes, F. E., Hobson, S. A., Wynick, D., Hökfelt, T., & Kofler, B. (2015) · Pharmacological Reviews · doi:10.1124/pr.112.006536 · Cited by 327
Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction
Mufson, E. J., Ginsberg, S. D., Ikonomovic, M. D., & DeKosky, S. T. (2003) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(03)00068-1 · Cited by 295
Neuropeptide and small transmitter coexistence: Fundamental studies and relevance to mental illness
Hökfelt, T., Barde, S., Xu, Z.-Q. D., Kuteeva, E., Rüegg, J., Le Maitre, E., Risling, M., Kehr, J., Ihnatko, R., Theodorsson, E., et al. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00106 · Cited by 139
Nilsson, C. L., Brinkmalm, A., Minthon, L., Blennow, K., & Ekman, R. (2001) · Peptides · doi:10.1016/s0196-9781(01)00571-x · Cited by 79
Podlasz, P., Sallinen, V., Chen, Y. ‐., Kudo, H., Fedorowska, N., & Panula, P. (2012) · Journal of Comparative Neurology · doi:10.1002/cne.23131 · Cited by 30
Metadata
- Authors
- Chan‐Palay, V.
- Venue
- Journal of Comparative Neurology
- Publisher
- Wiley
- Published
- 1988-07-22
- Volume
- 273
- Issue
- 4
- Pages
- 543-557
- ISSN
- 0021-9967 (ISSN-L)
- 1096-9861
- OpenAlex
- W2031247327
- Cited by
- 273
- References
- 46
- FWCI
- 12.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.